JP2012140459A - イソプロピルウノプロストンの分解抑制方法 - Google Patents
イソプロピルウノプロストンの分解抑制方法 Download PDFInfo
- Publication number
- JP2012140459A JP2012140459A JP2012088586A JP2012088586A JP2012140459A JP 2012140459 A JP2012140459 A JP 2012140459A JP 2012088586 A JP2012088586 A JP 2012088586A JP 2012088586 A JP2012088586 A JP 2012088586A JP 2012140459 A JP2012140459 A JP 2012140459A
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic solution
- isopropyl unoprostone
- trometamol
- decomposition
- isopropylunoprostone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 title claims abstract description 35
- 229950008081 unoprostone isopropyl Drugs 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims description 12
- 230000015556 catabolic process Effects 0.000 title abstract description 6
- 238000006731 degradation reaction Methods 0.000 title abstract description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960000281 trometamol Drugs 0.000 claims abstract description 18
- 239000002997 ophthalmic solution Substances 0.000 claims description 43
- 229940054534 ophthalmic solution Drugs 0.000 claims description 43
- 238000000354 decomposition reaction Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000003889 eye drop Substances 0.000 abstract description 12
- 239000000243 solution Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229960001160 latanoprost Drugs 0.000 description 9
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- -1 amine compound Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 229960004811 pemirolast potassium Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- NMMVKSMGBDRONO-UHFFFAOYSA-N potassium;9-methyl-3-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound [K+].CC1=CC=CN(C2=O)C1=NC=C2C1=NN=N[N-]1 NMMVKSMGBDRONO-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- UMYAMXGXQKNONL-UHFFFAOYSA-M C(CC(O)(C(=O)O)CC(=O)O)(=O)[O-].B(O)(O)O.[K+] Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)[O-].B(O)(O)O.[K+] UMYAMXGXQKNONL-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124342 antiallergic ophthalmic agent Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- IMBXEJJVJRTNOW-XYMSELFBSA-N methylprednisolone succinate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC(O)=O)CC[C@H]21 IMBXEJJVJRTNOW-XYMSELFBSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004458 tafluprost Drugs 0.000 description 1
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【解決手段】イソプロピルウノプロストンを含有する点眼液にトロメタモールを配合すれば、点眼液中のイソプロピルウノプロストンの分解を効果的に抑制でき、安定に保存できる。
【選択図】なし
Description
(1)イソプロピルウノプロストンを含有する点眼液にトロメタモールを配合することにより、点眼液中のイソプロピルウノプロストンの分解を抑制する方法、
(2)イソプロピルウノプロストンを含有する点眼液にトロメタモールを配合し、かつ、pHを4〜8の範囲とすることにより、点眼液中のイソプロピルウノプロストンの分解を抑制する方法、
(3)イソプロピルウノプロストンを含有する点眼液にトロメタモールを配合することにより、点眼液中のイソプロピルウノプロストンの分解が抑制された点眼液組成物、および
(4)イソプロピルウノプロストンを含有する点眼液にトロメタモールを配合し、かつ、pHを4〜8の範囲とすることにより、点眼液中のイソプロピルウノプロストンの分解が抑制された点眼液組成物、である。
熱的に不安定な薬物として、ラタノプロスト(化学名:イソプロピル−(Z)−7[(1R,2R,3R,5S)3,5−ジヒドロキシ−2−[(3R)−3−ヒドロキシ−5−フェニルペンチル]シクロペンチル]−5−ヘプタノエート)を用いて、熱安定性試験を行った。
処方1
トロメタモール1gを精製水約80mLに溶解し、希塩酸でpHを7.0に調整し、精製水で全量100mLとし、基剤とした。ラタノプロスト5mgに基剤100mLを加え、約80℃の水浴中で加温しながら撹拌し、ラタノプロストを溶解させた。これを室温に戻した後pHが7.0であることを確認した。
リン酸二水素ナトリウム(緩衝剤)1gを精製水約80mLに溶解し、1N水酸化ナトリウムでpHを7.0に調整し、精製水で全量100mLとし、基剤とした。ラタノプロスト5mgに基剤100mLを加え、約80℃の水浴中で加温しながら撹拌し、ラタノプロストを溶解させた。これを室温に戻した後pHが7.0であることを確認した。
処方1および比較処方1を5mLずつガラスアンプルに充填し、それぞれについて80℃で4週間および50℃で8週間保存した後、ラタノプロストの含有量を高速液体クロマトグラフィー(HPLC)を用いて定量し、残存率を求めた。試験結果を表1に示す。
表1から明らかなように、トロメタモールを配合した点眼液(試料1)のラタノプロストの残存率は、リン酸二水素ナトリウムを配合した点眼液(比較試料1)の残存率よりも大きい。したがって、熱的に不安定な薬物(ラタノプロスト)を含有する点眼液にトロメタモールを配合すれば、点眼液中の熱的に不安定な薬物の分解を効果的に抑制し、安定に保存できる。
Claims (4)
- イソプロピルウノプロストンを含有する点眼液にトロメタモールを配合することにより、点眼液中のイソプロピルウノプロストンの分解を抑制する方法。
- イソプロピルウノプロストンを含有する点眼液にトロメタモールを配合し、かつ、pHを4〜8の範囲とすることにより、点眼液中のイソプロピルウノプロストンの分解を抑制する方法。
- イソプロピルウノプロストンを含有する点眼液にトロメタモールを配合することにより、点眼液中のイソプロピルウノプロストンの分解が抑制された点眼液組成物。
- イソプロピルウノプロストンを含有する点眼液にトロメタモールを配合し、かつ、pHを4〜8の範囲とすることにより、点眼液中のイソプロピルウノプロストンの分解が抑制された点眼液組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012088586A JP5593345B2 (ja) | 2005-08-02 | 2012-04-09 | イソプロピルウノプロストンの分解抑制方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005223862 | 2005-08-02 | ||
JP2005223862 | 2005-08-02 | ||
JP2012088586A JP5593345B2 (ja) | 2005-08-02 | 2012-04-09 | イソプロピルウノプロストンの分解抑制方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010289627A Division JP2011057717A (ja) | 2005-08-02 | 2010-12-27 | イソプロピルウノプロストンの分解抑制方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014098810A Division JP2014141534A (ja) | 2005-08-02 | 2014-05-12 | イソプロピルウノプロストンの分解抑制方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012140459A true JP2012140459A (ja) | 2012-07-26 |
JP5593345B2 JP5593345B2 (ja) | 2014-09-24 |
Family
ID=37708790
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010289627A Pending JP2011057717A (ja) | 2005-08-02 | 2010-12-27 | イソプロピルウノプロストンの分解抑制方法 |
JP2012088586A Active JP5593345B2 (ja) | 2005-08-02 | 2012-04-09 | イソプロピルウノプロストンの分解抑制方法 |
JP2014098810A Pending JP2014141534A (ja) | 2005-08-02 | 2014-05-12 | イソプロピルウノプロストンの分解抑制方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010289627A Pending JP2011057717A (ja) | 2005-08-02 | 2010-12-27 | イソプロピルウノプロストンの分解抑制方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014098810A Pending JP2014141534A (ja) | 2005-08-02 | 2014-05-12 | イソプロピルウノプロストンの分解抑制方法 |
Country Status (5)
Country | Link |
---|---|
US (2) | US8030349B2 (ja) |
EP (1) | EP1916002B1 (ja) |
JP (3) | JP2011057717A (ja) |
ES (1) | ES2460967T3 (ja) |
WO (1) | WO2007015510A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019131881A (ja) * | 2018-02-02 | 2019-08-08 | 東邦チタニウム株式会社 | 溶融塩電解方法、溶融金属の製造方法および、溶融塩電解槽 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8030349B2 (en) * | 2005-08-02 | 2011-10-04 | Santen Pharmaceutical Co., Ltd. | Method for prevention of degradation of thermally unstable medicament |
EP2123278B1 (en) * | 2007-02-07 | 2013-01-09 | Teika Pharmaceutical Co., Ltd. | Eye drop preparation comprising latanoprost |
EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
EP2269575A1 (en) * | 2009-06-30 | 2011-01-05 | Santen Pharmaceutical Co., Ltd | Method for improving bioavailability of latanoprost |
WO2018033854A1 (en) | 2016-08-15 | 2018-02-22 | Santen Pharmaceutical Co., Ltd. | Ophthalmic composition and a method for treating ocular hypertension and glaucoma |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08291065A (ja) * | 1995-04-20 | 1996-11-05 | Santen Pharmaceut Co Ltd | 有機アミンを配合したプラノプロフェン点眼液 |
JP2001515502A (ja) * | 1997-03-17 | 2001-09-18 | ノバルティス アクチエンゲゼルシャフト | 高眼圧を低下させるための組成物及び方法 |
JP2003146881A (ja) * | 2001-11-14 | 2003-05-21 | Toyo Pharmar Kk | 抗アレルギー眼科用剤 |
WO2005023258A1 (en) * | 2003-09-05 | 2005-03-17 | Novartis Ag | Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives |
WO2005044276A1 (ja) * | 2003-11-07 | 2005-05-19 | Senju Pharmaceutical Co., Ltd. | プロスタグランジン含有医薬組成物 |
JP2005519905A (ja) * | 2002-01-25 | 2005-07-07 | グラクソ グループ リミテッド | Dnaの製剤 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4305947A (en) | 1980-08-26 | 1981-12-15 | Survival Technology, Inc. | Stable aqueous solutions of pralidoxime salts |
JP2849922B2 (ja) * | 1989-05-26 | 1999-01-27 | 吉富製薬株式会社 | プラスミノーゲン活性化因子含有液状組成物 |
US5767154A (en) | 1991-02-07 | 1998-06-16 | Allergan | 5-trans-prostaglandins of the F series and their use as ocular hypotensives |
US5288754A (en) * | 1992-02-04 | 1994-02-22 | Allergan, Inc. | Polar C-1 esters of prostaglandins |
US5631287A (en) * | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
US6770675B2 (en) * | 1997-03-17 | 2004-08-03 | Novartis Ag | Compositions and methods for reducing ocular hypertension |
US6235781B1 (en) | 1998-07-14 | 2001-05-22 | Alcon Laboratories, Inc. | Prostaglandin product |
CN1146423C (zh) * | 1998-07-14 | 2004-04-21 | 阿尔康实验室公司 | 前列腺素产品 |
CA2345466C (en) | 1998-09-25 | 2007-01-23 | Alcon Laboratories, Inc. | Sustained release, and comfortable ophthalmic composition and method for ocular therapy |
JP4431817B2 (ja) | 2002-03-08 | 2010-03-17 | 第一三共株式会社 | テトラゾール誘導体を含有する点眼剤 |
CA2488802A1 (en) | 2002-06-14 | 2003-12-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
US6864282B2 (en) | 2002-08-05 | 2005-03-08 | Allergan, Inc. | 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
JP4314429B2 (ja) | 2002-08-23 | 2009-08-19 | 参天製薬株式会社 | ラタノプロストを有効成分とする安定な点眼液 |
CA2496540C (en) | 2002-08-23 | 2011-01-25 | Santen Pharmaceutical Co., Ltd. | Stable ophthalmic solution comprising latanoprost as active ingredient |
JP2004307491A (ja) * | 2004-03-24 | 2004-11-04 | Taisho Pharm Ind Ltd | ヘパリン類似物質を含有する皮膚外用剤 |
US8030349B2 (en) * | 2005-08-02 | 2011-10-04 | Santen Pharmaceutical Co., Ltd. | Method for prevention of degradation of thermally unstable medicament |
-
2006
- 2006-08-02 US US11/989,128 patent/US8030349B2/en active Active
- 2006-08-02 EP EP06782153.8A patent/EP1916002B1/en active Active
- 2006-08-02 ES ES06782153.8T patent/ES2460967T3/es active Active
- 2006-08-02 WO PCT/JP2006/315284 patent/WO2007015510A1/ja active Application Filing
-
2010
- 2010-12-27 JP JP2010289627A patent/JP2011057717A/ja active Pending
-
2011
- 2011-07-28 US US13/136,309 patent/US8324271B2/en not_active Expired - Fee Related
-
2012
- 2012-04-09 JP JP2012088586A patent/JP5593345B2/ja active Active
-
2014
- 2014-05-12 JP JP2014098810A patent/JP2014141534A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08291065A (ja) * | 1995-04-20 | 1996-11-05 | Santen Pharmaceut Co Ltd | 有機アミンを配合したプラノプロフェン点眼液 |
JP2001515502A (ja) * | 1997-03-17 | 2001-09-18 | ノバルティス アクチエンゲゼルシャフト | 高眼圧を低下させるための組成物及び方法 |
JP2003146881A (ja) * | 2001-11-14 | 2003-05-21 | Toyo Pharmar Kk | 抗アレルギー眼科用剤 |
JP2005519905A (ja) * | 2002-01-25 | 2005-07-07 | グラクソ グループ リミテッド | Dnaの製剤 |
WO2005023258A1 (en) * | 2003-09-05 | 2005-03-17 | Novartis Ag | Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives |
WO2005044276A1 (ja) * | 2003-11-07 | 2005-05-19 | Senju Pharmaceutical Co., Ltd. | プロスタグランジン含有医薬組成物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019131881A (ja) * | 2018-02-02 | 2019-08-08 | 東邦チタニウム株式会社 | 溶融塩電解方法、溶融金属の製造方法および、溶融塩電解槽 |
Also Published As
Publication number | Publication date |
---|---|
EP1916002A4 (en) | 2010-04-07 |
JP5593345B2 (ja) | 2014-09-24 |
ES2460967T3 (es) | 2014-05-16 |
EP1916002B1 (en) | 2014-03-05 |
US8030349B2 (en) | 2011-10-04 |
JP2011057717A (ja) | 2011-03-24 |
JP2014141534A (ja) | 2014-08-07 |
US8324271B2 (en) | 2012-12-04 |
WO2007015510A1 (ja) | 2007-02-08 |
EP1916002A1 (en) | 2008-04-30 |
US20110295034A1 (en) | 2011-12-01 |
US20090264523A1 (en) | 2009-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5087702B2 (ja) | ラタノプロストを有効成分とする澄明な点眼液 | |
JP5593345B2 (ja) | イソプロピルウノプロストンの分解抑制方法 | |
JP3933683B2 (ja) | アジスロマイシン含有水性医薬組成物及びその調製方法 | |
JP5661456B2 (ja) | 点眼剤及び使用方法 | |
JP2008528490A (ja) | 安定なプロスタグランジン含有組成物 | |
KR20160060656A (ko) | 폴리에틸렌글리콜 함유 조성물 | |
EP1532981B1 (en) | Stable eye drops containing latanoprost as the active ingredient | |
JP2005263792A (ja) | 澄明なラタノプロスト点眼液 | |
JP5252787B2 (ja) | 熱的に不安定な薬物の分解抑制方法 | |
JP7062846B1 (ja) | 安定な医薬組成物 | |
JP5253775B2 (ja) | ラタノプロスト点眼剤 | |
JP4314429B2 (ja) | ラタノプロストを有効成分とする安定な点眼液 | |
JP5420877B2 (ja) | 眼科用剤 | |
JP2004123729A (ja) | ラタノプロストを有効成分とする澄明な点眼液 | |
JP2007016024A (ja) | ロフルミラスト点眼液 | |
JP2009256281A (ja) | イソプロピルウノプロストン含有点眼剤組成物 | |
TW201836611A (zh) | 含有他氟前列素及檸檬酸酯之緩釋劑 | |
JP6628924B2 (ja) | 水性液剤 | |
JP2010132572A (ja) | 眼科用剤 | |
WO2005079809A1 (ja) | 澄明なラタノプロスト点眼液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120508 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130920 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131121 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140512 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140701 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140729 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140804 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5593345 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |